Investment Thesis
Elevance Health demonstrates stable cash generation ($4.1B FCF) and strong revenue growth (12.5% YoY), but concerning operational trends—flat net income despite revenue expansion and declining EPS—indicate margin compression in a highly competitive healthcare insurance market. Financial position is adequate but capital efficiency is weak (ROE 4.0%), making the company defensible but not compelling.
Strengths
- Strong free cash flow generation of $4.1B with 8.2% FCF margin—significantly outpaces net income, indicating resilient operations
- Revenue growth of 12.5% YoY demonstrates market share gains and premium volume expansion in core business
- Low capital intensity ($235M CapEx on $50.2B revenue) enables consistent cash returns despite minimal reinvestment needs
- Adequate liquidity position (1.48x current ratio) and moderate leverage (0.71x D/E) provide financial flexibility
Risks
- Net income flat YoY despite 12.5% revenue growth signals margin compression and deteriorating operational leverage
- Diluted EPS declining 1.8% YoY indicates shareholder value creation is stalling; profitability trends reversing
- Thin operating (4.2%) and net margins (3.5%) leave minimal room for medical cost inflation or competitive pricing pressure—typical insurance risk
- Poor capital returns (ROE 4.0%, ROA 1.4%) suggest shareholder capital is not efficiently deployed despite asset base of $125.8B
- Interest coverage of 2.5x is tight given $31.1B long-term debt; limited cushion if underwriting deteriorates
Key Metrics to Watch
- Medical loss ratio and operating expense trends—critical to confirm whether margin compression stabilizes or worsens
- Net income and EPS growth direction in coming quarters; must show inflection from current flat trajectory
- Free cash flow conversion and sustainability as revenue growth moderates in mature insurance market
- Return on equity trend and whether capital is increasingly returned to shareholders versus retained earnings growth
Financial Metrics
Revenue
50.2B
Net Income
1.8B
EPS (Diluted)
$8.00
Free Cash Flow
4.1B
Total Assets
125.8B
Cash
9.7B
Profitability Ratios
Gross Margin
N/A
Operating Margin
4.2%
Net Margin
3.5%
ROE
4.0%
ROA
1.4%
FCF Margin
8.2%
Balance Sheet & Liquidity
Current Ratio
1.48x
Quick Ratio
1.48x
Debt/Equity
0.71x
Debt/Assets
65.0%
Interest Coverage
2.47x
Long-term Debt
31.1B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-29T13:49:27.462380 |
Data as of: 2026-03-31 |
Powered by Claude AI